中国临床药学杂志2024，Vol.33Issue(4)：251-254,4.DOI:10.19577/j.1007-4406.2024.04.003
门诊化疗静脉用药集中调配安全模式的构建与评价
Establishment and evaluation of centralized preparation safety models for outpatient chemotherapy intravenous medication
摘要
Abstract
AIM To incorporate outpatient chemotherapy into the pharmaceutical quality control management system,provide high-standard pharmacy intravenous admixture service for cancer patients,and ensure drug safety in patients,enhance the patient treatment experience.METHODS Based on the current situation,a reasonable and complete pharmacy intravenous admixture service for outpatient chemotherapy was established through information system support,overall personnel arrangement,workflow design,and other measures.The effect of outpatient chemotherapy was evaluated in three aspects:irrational medical orders,patient satisfaction,and nurse satisfaction.RESULTS The system covered the construction,operation,quality control,and management and met the needs of outpatient chemotherapy treatment.After the operation of the management system,the proportion of irrational medical orders decreased significantly(P＜0.05).Patient satisfaction in the treatment process,health education,and nursing services increased(P＜0.05).Lastly,the fulfillment of nurses in occupational protection and the working process increased,with a statistically significant difference(P＜0.05).CONCLUSION The centralized preparation safety model for outpatient chemotherapy intravenous medication,by integrating the entire medication process for outpatient chemotherapy patients into the pharmaceutical quality control management system,can comprehensively improve the quality of intravenous drug use and hospital service efficiency,providing a reference for professionals in this field.关键词
门诊化疗/静脉用药集中调配/药事质控管理Key words
outpatient chemotherapy/pharmacy intravenous admixture service/pharmaceutical quality control management引用本文复制引用
张叶叶,张建中,李晓宇,吕迁洲,老东辉..门诊化疗静脉用药集中调配安全模式的构建与评价[J].中国临床药学杂志,2024,33(4):251-254,4.基金项目
复旦大学附属中山医院青年基金(编号2023ZSQN13) （编号2023ZSQN13）
中华医学会临床药学分会-临床药学科研基金项目(编号Z-2021-46-2101-2023) （编号Z-2021-46-2101-2023）
